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1α,25-Dihydroxyvitamin D3 Protects Dopaminergic 
Neurons in Rodent Models of Parkinson’s Disease 
through Inhibition of Microglial Activation
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Background: Recent studies have demonstrated the molecular basis of the immunomodulatory and anti- 
inflammatory activities of 1,25-dihydroxyvitamin D3(1,25-(OH)2D3). This hormone improves behavioral deficits and 
normalizes the nigral dopamine levels in animal models of Parkinson’s disease (PD).
Methods:  We  studied  whether  the  administration  of  1,25-(OH)2D3 w o u l d  p r o t e c t  a g a i n s t  6 - h y d r o x y d o p a  
(6-OHDA)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuronal injury, and its potential 
regulatory effect on microglia activation.
Results: We found that 1,25-(OH)2D3 pretreatment significantly decreased 6-OHDA- and MPTP-induced 
dopaminergic neuronal loss in the substantia nigra pars compacta by preventing the activation of microglia. This 
observed neuroprotective effect in MPTP-treated mice that were given 1,25-(OH)2D3 may be attributable to inhibition 
of proinflammatory cytokine expression. 
Conclusion: These results suggest that 1,25-(OH)2D3 is a potentially valuable neuroprotective agent; it may 
therefore be considered for the treatment of pathologic conditions of the central nervous system, such as PD, 
where inflammation-induced neurodegeneration occurs.
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INTRODUCTION
The etiology of sporadic Parkinson’s disease (PD) 
remains unknown, but there is increasing evidence of a 
role of inflammation in the brain as a factor in its 
pathogenesis.
1  Microglia, the resident immune cells in 
the brain, play a role in immune surveillance under 
normal conditions, and become readily activated in 
response to injuries in the brain and immunologic 
challenges. Activated microglia produce a wide array of 
cytotoxic factors, including tumor necrosis factor-α (TNF
α), interleukin (IL)-1β, eicosanoids, nitric oxide, and 
reactive oxygen species that impact neurons and induce 
neurodegeneration.
1  Evidence of microglial activation 
has been derived mostly from postmortem analyses of 
the substantia nigra of PD patients.
2
The active metabolite of vitamin D3, 1,25-dihydroxy-
vitamin D3(1,25-(OH)2D3), has been reported to exert 
profound anti-inflammatory and immunosuppressive Kim JS, et al. 1α,25-Dihydroxyvitamin D3 Protects Dopaminergic Neurons in Rodent Models of Parkinson’s Disease
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effects. This hormone inhibits B- and T-lymphocyte 
proliferation, downregulates the production of IL-2 and 
interferon (IFN)γ by T lymphocytes, and prevents 
immunoglobulin secretion by B lymphocytes.
3 More-
over, 1,25-(OH)2D3 enhances endogenous glial cell-line- 
derived neurotrophic factor (GDNF) expression in vitro 
and in vivo,
4,5 which is believed to play an important 
role in microglial activation.
In the present study, we investigated the potential neuro-
protective effect of 1,25-(OH)2D3 against 6-hydroxy-
dopa (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) toxicity in rodent models of PD.
METHODS
1. Model 1: 6-OHDA in rats
A total of 24 adult male Sprague-Dawley rats (weight 
250 – 300 g) were used. These animals received 
either a daily dose of 1,25-(OH)2D3 ( n=12, 1 μg/ml 
at 1 ml/kg/day; Bonky, Calcitriol, Yuyu, Anyang, 
Korea) or a vehicle (n=12, ethanol 0.1%, 1 ml/kg; 
Merck, Darmstadt, Germany), injected intraperitoneally 
for 7 consecutive days. On the 7th day of injection, the 
animals were anesthetized and injected unilaterally with 
6-OHDA (8μg/3μl in normal saline containing 0.2 mg/ml 
ascorbic acid; Merick, MA, USA) over 5 min using a 
Hamilton syringe into the medial forebrain bundle 
(coordinates: 4.3 mm posterior from bregma, 1.4 mm 
from the midline relative to the bregma, and 8.4 mm 
below the dural surface).
Locomotor activity was tested with the aid of 
apomorphine (0.1 mg/kg injected subcutaneously) 4 
weeks after inflicting unilateral 6-OHDA lesions. Rats 
were killed 4 weeks after surgery, and their brains 
were fixed and processed for immunohistochemical 
staining as described previously.
6 The primary antibodies 
used in this study were as follows: rabbit polyclonal 
anti-tyrosine-hydroxylase (TH) antibody (diluted 
1:1000; Santa Cruz Biotechnology, CA, USA) and 
mouse monoclonal anti-rat-CD11b antibody (diluted 
1:500; OX-42, Serotec, Oxford, UK). Immunostaining 
was visualized using the Envision
TM detection kit 
(K5007, Dako, Carpinteria, CA, USA) and 3,3- 
diaminobenzidine (Sigma, St Louis, MO, USA) 
containing 0.01% H2O2. Coronal 30-μm-thick sections of 
the substantia nigra were made (coordinates: bregma 
-5.30 mm, interaural 3.70 mm), and measurements were 
made on pairs of sections separated from each other by 
300  μm.
7 The numbers of TH-immunoreactive neurons 
and activated microglia (CD11b-immunoreactive cells) 
were counted in each section from normal and lesioned 
substantia nigra pars compacta (SNpc), while viewing at 
a magnification of x100. Average numbers of immuno-
reactive cells per section were calculated. The ANOVA 
with two variables test was used for statistical analysis.
2. Model 2: MPTP in mice
A total of 56 C57BL/6 mice weighing 25-30 g 
received a daily intraperitoneal injection of either 
1,25-(OH)2D3 (n=28, 1μg/ml at 1 ml/kg/day; Bonky, 
Calcitriol) or vehicle (n=28, ethanol 0.1%, 1 ml/kg  
Merck) for 7 consecutive days. On the 7th day of 
injection, the animals also received four intraperitoneal 
injections of 20 mg/kg MPTP (calculated as free base, 
dissolved in 0.9% saline solution) at 2-h intervals. 
Control mice received saline, which was administered 
using the same administration schedule (n=16).
The mice were sacrificed, transcardial perfusion 
fixation was performed at 24 or 48 h after MPTP 
injection, and the brains were fixed and processed for 
immunohistochemical staining as described above. 
Measurements were made only for those cells that fell 
clearly within the confines of the substantia nigra 
(coordinates: bregma -3.16 mm, interaural 0.64 mm) in 
three coronal sections that were 30-μm thick and 
separated from each other by 300 μm.
8
To investigate the temporal pattern of expression of 
the key cytokines involved in inflammation and immune 
responses (IFNγ and TNFα), gene expression was 
quantified using a modification of a previously described 
reverse transcriptase (RT)-polymerase chain reaction 
(PCR) method.
9 Animals were killed by spinal cord 
dislocation and then decapitated at 4, 12, 24, or 48 h 
after MPTP intoxication (3 animals for each time 
point). RNA was prepared from the substantia nigra, as Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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Figure 1. Expression of TH-immunoreactive cells and activated microglia in the SNpc. (A) TH-positive cell loss following 6-OHDA 
injection. (B) Microglia reaction after 6-OHDA injection. (C) TH-positive cell loss after intraperitoneal MPTP injection. (D) Microglia 
reaction after MPTP injection. Cells represent numbers of immunoreactive cells per section (mean±SD values). *P<0.05 
†P<0.01.
described previously. Briefly, after the RT reaction the 
cDNA was amplified using the following primers: IFNγ, 
forward: AGC GGC TGA CTG AAC TCA GAT TGT 
AG (26-mer), reverse: GGTC ACA GTT TTC AGC 
TGT ATA GGG (25-mer); TNFα, forward: GGC AGG 
TCT ACT TTG GAG TCA TTG C (25-mer), reverse: 
ACA TTC GAG GCT CCA GTG AAT TCG G 
(25-mer); and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), forward: TGA AGG TCG GAG TCA ACG 
GAT TTG GT (26-mer), reverse: CAT GTG GGC CAT 
GAG GTC CAC CAC (24-mer). As a control for 
genomic contamination, a sample without RT was added 
to each PCR analysis. To eliminate sample- to-sample 
differences in RNA extraction and conversion to cDNA, 
we amplified the housekeeping gene GAPDH. The 
thermal cycling parameters were as follows: 35 cycles of 
95℃ for 2 min, 94℃ for 50 s, 60℃ for 50 s, and 72℃ 
for 1 min; 72℃ for 5 min for TNFα and INFγ and 30 
cycles of 94℃ for 10 min, 94℃ for 30 s, 57℃ for 30 s, 
and 72℃ for 30 s; 72℃ for 10 min for GAPDH. PCR 
products were separated on 1% agarose gels stained with 
ethidium bromide and visualized with the aid of UV 
light and a camera linked to an image analyzer. The 
results are expressed in relative units, as determined by 
normalization of the optical density of each band to that 
of the GAPDH band. Three cytokine PCR assays were 
performed for each group and all results were analyzed 
statistically using the Mann-Whitney U test.Kim JS, et al. 1α,25-Dihydroxyvitamin D3 Protects Dopaminergic Neurons in Rodent Models of Parkinson’s Disease
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Figure 2. Representative RT-PCR demonstrating the expression of TNFα (A), INFγ (B), and GAPDH (C) mRNAs, and the expression 
pattern of the TNFα (D) and INFγ (E) mRNA in the SNpc at various times after MPTP intoxication. Data are mean±SEM values 
(n=3). *P<0.05, Mann-Whitney U test.
RESULTS
1. 6-OHDA model in rats
The loss of TH-immunoreactive cells in the 
ipsilateral SNpc reached 58% at 4 weeks after 
6-OHDA injection relative to the noninjected side 
(lesioned substantia nigra, 48.27±12.42 cells, mean± 
SD; nonlesioned substantia nigra, 114.12±9.84, 
P<0.01,  n=12). 1,25-(OH)2D3 pretreatment protected 
against 6-OHDA-mediated damage in the SNpc 
(lesioned SNpc, 77.93±9.52; nonlesioned, 118.34± 
12.90,  P<0.05,  n=12; Fig. 1A). In 1,25-(OH)2D3- 
pretreated, 6-OHDA-injected rats, only a few im-
munoreactive activated microglia were observed in 
the ipsilateral SNpc (12.24±11.31). In contrast, 
vehicle-treated, 6-OHDA-injected rats exhibited a 
more intense expression of activated microglia along 
the lesioned SNpc (65.38±9.82, P<0.01; Fig. 1B).
2. MPTP model in mice
MPTP exposure led to a more than 54% loss of 
TH-positive neurons (117.3±24.6 vs. 252.6±16.8, 
P<0.01, 24 h, n=8; and 104.6±25.2 vs. 258.4±22.3, 
P<0.01, 48 h, n=8 Fig. 1C). Pretreatment with 1,25- 
(OH)2D3 protected this reduction in nigral TH im-
munoreactivity. The mean number of TH-positive 
neurons was significantly higher in the 1,25-(OH)2D3 
-treated groups than in the MPTP- and vehicle- 
treated groups (214.7±12.6 vs. 117.3±24.6, P<0.01, 
24 h, n=8; and 188.6±31.3 vs. 104.6±25.2; P<0.01, 
48 h, n=8 Fig. 1C). In 1,25-(OH)2D3-treated mice, 
there was an approximately 73% inhibition of 
microglia activation in the number of microglial 
profiles at 24 h after MPTP injection compared with 
those MPTP mice that were not given 1,25-(OH)2D3 Journal of Clinical Neurology: Vol. 2, No. 4, 2006
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(1,25-(OH)2D3 group, 21.22±13.33; ethanol group, 
77.32±12.21,  P<0.01; Fig. 1D).
RT-PCR analysis revealed a similar pattern in the 
kinetics of INFγ and TNFα mRNA expression following 
MPTP injection (Fig. 2). A rapid increase in the amount 
of mRNA for INFγ and TNFα was observed between 4 
and 24 h after MPTP injection. Comparison with the 
vehicle-treated group revealed that pretreatment with 
1,25-(OH)2D3 protected against the overexpression of 
proinflammatory cytokines.
DISCUSSION
Our experiments employed two representative pharma-
cologically generated rodent models of PD. The 6- 
OHDA-lesioned rat is a well-validated model for motor 
alteration related to the advanced phases of PD. 
Moreover, the systematic injection of MPTP in mice 
may be considered a good model of acute-phase PD, 
which can cause sustained nigral degeneration, bio-
chemical changes, and motor abnormalities.
10,11
The main finding of this study is that inhibition of 
microglial activation by pretreatment with 1,25-(OH)2D3 
protects against nigrostriatal degeneration in a rodent 
model of PD. In rats that received 1,25-(OH)2D3, 
protective effects against 6-OHDA were confirmed by 
histopathological findings. These effects were also 
identified in the MPTP-induced acute mouse model of 
PD.
In mice that received 1,25-(OH)2D3, the neuro-
protective effect of 1,25-(OH)2D3 might be related to a 
decrease in proinflammatory cytokines. The detection of 
elevated levels of proinflammatory cytokines in post-
mortem PD brains provides strong evidence that 
microglia are involved in the degenerative process.
12  The 
important role of activated microglia in inflammation- 
mediated neurodegeneration and potentially in the path-
ogenesis of PD, prompted us to speculate that the 
inhibition of microglial activation by 1,25-(OH)2D3 is 
neuroprotective. The result of this experiment, that 
1,25-(OH)2D3 appeared to attenuate the neurotoxin- 
induced microglial activation and expression of proin-
flammatory cytokines, raises the possibility that 1,25- 
(OH)2D3 is neuroprotective in experimental models of 
inflammation-mediated neurodegenerative disease.
Other mechanisms may also be involved in the 
neuroprotective effects of 1,25-(OH)2D3 in preventing 
nigral degeneration. First, 1,25-(OH)2D3 treatment might 
enhance GDNF mRNA and protein expression in the 
striatum.
5 A previous study has shown that the exo-
genous administration of GDNF reduces the toxicity of 
MPTP- and 6-OHDA-induced nigral dopaminergic cell 
injury.
13  Second, the influence on the antioxidant defense 
mechanisms of 1,25-(OH)2D3 may play a role in the 
pathogenesis of nigral cell damage.
14,15 
Our results suggest that 1,25-(OH)2D3 is a potentially 
valuable neuroprotective agent that may be used for the 
treatment of pathologic conditions of the central nervous 
system, such as PD, where inflammation-induced neuro-
degeneration occurs. Further study is planned to evaluated 
the efficacy of 1,25-(OH)2D3 for the treatment of PD 
and associated neurodegenerative disorders.
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